Complement C4d in graft capillaries - The missing link in the recognition of humoral alloreactivity

American Journal of Transplantation

Volumn 3, Issue 6, 2003, Pages 646-652

  Feucht, Helmut E ^a  

^a Fachklinik Bad Heilbrunn ^*  (Germany)

Author keywords

Complement C4d; Graft rejection; Humoral alloreactivity

Indexed keywords

COMPLEMENT COMPONENT C4D; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGRAFT; ALLOIMMUNITY; ANTIBODY PRODUCTION; BIOPSY; CAPILLARY; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; IMMUNOHISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; ORGAN DONOR; PLASMAPHERESIS; SHORT SURVEY;

ANIMALS; ANTIBODY FORMATION; CAPILLARIES; COMPLEMENT C4; COMPLEMENT C4B; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; ISOANTIBODIES; ORGAN TRANSPLANTATION; PEPTIDE FRAGMENTS; TRANSPLANTS;

EID: 0037869413     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00171.x     Document Type: Short Survey

References (46)

1. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422.
2. Martin S, Taylor CJ. The immunologically sensitised renal transplant recipient. The impact of advances in technology on organ allocation and transplant outcome. Transpl Rev 1999; 13: 40-51.
3. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The signification of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550-555.
4. Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody: analysis using the Banff grading schema. Transplantation 1996; 61: 1586-1592.
5. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319-326.
6. Morton AL, Bell EB, Bolton EM et al. CD4+ T cell-mediated rejection of major histocompatibility complex class I-disparate grafts: a role for alloantibody. Eur J Immunol 1993; 23: 2078-2084.
7. Russell PS, Chase CM, Colvin RB. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 1997; 64: 1531-1536.
8. Feucht HE, Felber E, Gokel JM et al. Vascular deposition of complement split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464-470.
9. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Editorial review. Kidney Int 1996; 50: 1464-1475.
10. Barilla-LaBarca ML, Liszewski KM, Lambris JD, Hourcade D, Atkinson JP. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J Immunol 2002; 168: 6298-6304.
11. Van den Eisen JMH, Martin A, Wong V, Clemenza L, Rose DR, Isenman DE. X-ray crystal structure of the C4d fragment of human complement component C4. J Mol Biol 2002; 322: 1103-1115.
12. Zwirner J, Felber E, Herzog V, Riethmüller G, Feucht HE. Classical pathway of complement activation in normal and diseased human glomeruli. Kidney Int 1989; 36: 1069-1077.
13. Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338.
14. Mauiyyedi S, Crespo M, Collins BAet al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779-787.
15. Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242-251.
16. Mauiyyedi S, Della Pelle P, Saidman S et al. Chronic humoral rejection. Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582.
17. Baldwin WM, III, Samaniego-Picota M, Kasper EK et al. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation 1999; 68: 894-900.
18. Behr TM, Feucht HE, Richter K et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999; 9: 904-912.
19. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59: 334-341.
20. Regele H, Böhmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380.
21. Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002; 11: 609-618.
22. Collins BA, Schneeberger EE, Pascual MA et al. Complement activation in acute humoral renal allograft rejection. Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214.
23. Mathew M, Bolton WK. Linear C3 deposits on the tubular basement membrane in renal allograft biopsies. Am J Kidney Dis 1988; 12: 121-125.
24. Bechtel U, Scheuer R, Landgraf R, König A, Feucht HE. Assessment of soluble cell adhesion molecules (sICAM-1, sVCAM-1, sELAM-1) and complement cleavage products (C4d, C5c-9) in urine: clinical monitoring of renal graft recipients. Transplantation 1994; 58: 905-911.
25. Magro CM, Deng A, Pope-Harman A et al. Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation 2002; 74: 1273-1280.
26. Regele H, Exner M, Watschinger B et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16: 2058-2066.
27. Zwirner J, Felber E, Schmidt P, Riethmüller G, Feucht HE. Complement activation in human lymphoid germinal centres. Immunology 1989; 66: 270-277.
28. Böhmig GA, Regele H, Exner M et al. C4d-positive acute humoral renal allograft rejection: Effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12: 2482-2489.
29. Racusen L, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
30. Nickerson P, Jeffery J, Gough J et al. Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 1998; 9: 482-487.
31. Haas M, Ratner LE, Montgomery RA. C4d staining of perioperative renal transplant biopsies. Transplantation 2002; 74: 711-717.
32. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582-587.
33. Lederer SR, Schneeberger H, Albert E et al. Early renal graft dysfunction. The role of preformed antibodies to DR-typed lymphoblastoid cell lines. Transplantation 1996; 61: 313-319.
34. Böhmig GA, Exner M, Habicht A et al. Capillary C4d deposition in kidney allografts. A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091-1099.
35. Crespo M, Pacual M, Tolkoff-Rubin N et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-658.
36. Herzenberg AM, Gill JS, Djurdjev O, Magil AB. C4d deposition in acute rejection: An independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234-241.
37. Süsal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73: 1269-1273.
38. Muczynski KA, Cotner T, Anderson SK. Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium. Kidney Int 2001; 59: 488-497.
39. Onitsuka S, Yamaguchi Y, Tanabe K, Takahashi K, Toma H. Peritubular capillary deposition of C4d complement fragment in ABO-incompatible renal transplantation with humoral rejection. Clin Transplantation 1999; 13 (Suppl. 1): 33-37.
40. Paul LC, van Es LA, van Rood JJ, van Leeuwen A, de la Riviere GB, de Graeff J. Antibodies directed against antigens on the endothelium of peritubular capillaries in patients with rejecting renal allografts. Transplantation 1979; 27: 175-179.
41. Platt JL. C4d and the fate of organ allografts. J Am Soc Nephrol 2002; 13: 2417-2419.
42. Yard B, Spruyt-Gerritse M, Claas F et al. The clinical significance of allospecific antibodies against endothelial cells detected with an antibody-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation. Transplantation 1993; 55: 1287-1293.
43. Baldwin WM, III, Qian Z, Wasowska B, Sanfilippo F. Complement causes allograft injury by cell activation rather than lysis. Transplantation 1999; 67: 1498-1499.
44. Haas M, Böhmig GA, Leko-Mohr Z et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002; 17: 1503-1508.
45. Theruvath TP, Saidman SL, Mauiyyedi S et al. Control of antidonor antibody production with tacrolimus and mycophenolat mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72: 77-83.
46. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.